Analysis of outcomes reveals increased CMV viremia and malignancy risks in older patients, highlighting the need for targeted immunosuppression strategies.
Key Points
Older kidney transplant recipients face a higher risk of CMV viremia, especially among females, and malignancy, particularly in males.
The HR for CMV viremia in recipients over 60 years was 2.66, with malignancy showing an HR of 7.3 compared to younger groups.
Immunosuppression strategies require adjustments to better accommodate age and sex, as older recipients show distinct complication trends.
Development of donor-specific anti-HLA antibodies was consistent across all age groups, indicating no significant disparity.